Astrazeneca Submits Seroquel XRâ„¢ In Europe For The Treatment Of Major Depressive Disorder

AstraZeneca announced that the company has submitted applications in the European Union (EU) for once-daily SEROQUEL XRâ„¢ (quetiapine fumarate) Extended-Release Tablets (quetiapine XR), seeking approval for the treatment of major depressive disorder (MDD) including maintenance therapy in adult patients using Mutual Recognition Procedure (MRP). This follows an sNDA submission for SEROQUEL XR in MDD in the U.S. in February this year.